Dabur India (DABUR) Q4 97/98 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 97/98 earnings summary
23 Oct, 2026Executive summary
FY98 turnover including other income reached Rs 824.80 crore; sales turnover was Rs 811.36 crore, with profit after tax of Rs 44.39 crore.
Project Stars, informed by McKinsey recommendations, refocused strategy on core FMCG strengths, operating efficiency and shareholder value.
Strategic plan targeted Rs 2,000 crore turnover by 2003, with a narrower portfolio and emphasis on 12–15 major brands.
Financial highlights
FY98 sales turnover was Rs 811.36 crore vs Rs 706.81 crore in FY97; turnover including other income was Rs 824.80 crore vs Rs 721.71 crore.
Profit before tax was Rs 45.37 crore vs Rs 42.57 crore; profit after tax was Rs 44.39 crore vs Rs 42.90 crore.
Other income included Rs 117.79 lacs profit on asset sales, including Rs 100.66 lacs capital profit; strategic management consultancy costs of Rs 149.37 lacs were written off.
Directors recommended a 35% dividend, or Rs 3.50 per share, vs 30% for FY97.
Outlook and guidance
Turnover target reset to Rs 2,000 crore by 2003, with growth centered on core competencies and fewer, stronger brands.
Planned priorities included supply-chain and procurement efficiency, distribution, sales-force effectiveness, lower manufacturing costs and quality improvements.
Plans included US launches of traditional herbal products through a separate subsidiary; registrations for anti-cancer products were targeted in Thailand, South Africa, Hungary and Turkey during FY99.
A professional CEO was being recruited to lead day-to-day management as promoters shifted toward strategic direction.
Latest events from Dabur India
- Q2 revenue reached ₹3,563.07 crore; a ₹3.50 interim dividend was declared.DABUR
Q2 26/27 - Revenue and PAT advanced as exports and manufacturing capacity expanded.DABUR
Q4 96/97 - Sales rose 13.5%; core growth offset restructuring costs and a slower FMCG market.DABUR
Q4 99/00 - Sales grew 12.7% as restructuring sharpened focus on core growth businesses.DABUR
Q4 98/99 - Flat sales, lower reported profit, and investment in global oncology growth.DABUR
Q4 01/02 - Sales outpaced a slow FMCG market as adjusted profit rose 39.2% and debt fell 32%.DABUR
Q4 00/01 - Profit rose 32.1% as efficiencies offset weak FMCG demand and restructuring advanced.DABUR
Q4 02/03 - Revenue rose 9.5% and PAT 40.6% despite weak FMCG demand.DABUR
Q4 03/04 - FY05 delivered higher growth and margins; Balsara broadened the portfolio as input-cost risks persisted.DABUR
Q4 04/05